These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19786662)

  • 1. Geographic distribution of lapatinib-induced skin rash: sparing of abdominal skin persists in the transverse rectus abdominis myocutaneous flap.
    Lin NU; Kasparian E; Morganstern DE; Beard C
    J Clin Oncol; 2009 Dec; 27(34):e218-9. PubMed ID: 19786662
    [No Abstract]   [Full Text] [Related]  

  • 2. Carcinoma en cuirasse: uncontrolled local recurrence of breast carcinoma after transverse rectus abdominis myocutaneous flap reconstruction.
    Wells DC; Loyer E; Libshitz HI
    AJR Am J Roentgenol; 1997 Sep; 169(3):914-5. PubMed ID: 9275930
    [No Abstract]   [Full Text] [Related]  

  • 3. Transverse rectus abdominis myocutaneous flap wound-healing complications in breast reconstruction: assisted closure using foam suction dressing.
    Giacalone PL; El Gareh N; Rihaoui S; Giovannini U
    Breast J; 2006; 12(5):481-4. PubMed ID: 16958970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How important is the pus culture obtained from epithelial growth factor receptor (EGFR) inhibitors' associated rash?
    Cholongitas E; Kokolakis G; Ioannidou D
    Int J Dermatol; 2008 Nov; 47(11):1203-4. PubMed ID: 18986464
    [No Abstract]   [Full Text] [Related]  

  • 5. Pyoderma gangrenosum following free transverse rectus abdominis myocutaneous breast reconstruction: a case report.
    Schoemann MB; Zenn MR
    Ann Plast Surg; 2010 Feb; 64(2):151-4. PubMed ID: 20098097
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.
    Parma J; Pavlick A; Schiff R; Osborne CK; Chang JC; Rimawi M; Trivedi MV
    Pharmacotherapy; 2013 Oct; 33(10):1126-9. PubMed ID: 23744830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rare case of umbilical metastasis after delayed transverse rectus abdominis myocutaneous flap reconstruction for invasive breast cancer.
    Seymour NC; Rathinaezhil R
    Breast Dis; 2017; 37(1):33-35. PubMed ID: 28035905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib-induced skin manifestations.
    Motoki T; Mitsuishi T; Kawana S
    J Dermatol; 2009 Dec; 36(12):658-9. PubMed ID: 19958452
    [No Abstract]   [Full Text] [Related]  

  • 9. Giant phyllodes tumour of the breast.
    Walravens C; De Greef C
    J Plast Reconstr Aesthet Surg; 2008 Oct; 61(10):e9-11. PubMed ID: 18042445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilonidal cyst of the breast.
    Ferdinand RD; Scott DJ; McLean NR
    Br J Surg; 1997 Jun; 84(6):784. PubMed ID: 9189085
    [No Abstract]   [Full Text] [Related]  

  • 11. The longitudinal gracilis myocutaneous flap: broadening options in breast reconstruction.
    Kind GM; Foster RD
    Ann Plast Surg; 2008 Nov; 61(5):513-20. PubMed ID: 18948778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
    Treudler R; Zouboulis CC
    Dermatology; 2005; 211(4):375-6. PubMed ID: 16286753
    [No Abstract]   [Full Text] [Related]  

  • 13. Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva).
    Lübbe J; Masouyé I; Dietrich PY
    Dermatology; 2008; 216(3):247-9. PubMed ID: 18182820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib-associated dermatological toxicity.
    Mumoli N; Cei M; Vitale J
    QJM; 2013 Apr; 106(4):363-4. PubMed ID: 22927541
    [No Abstract]   [Full Text] [Related]  

  • 15. Trichomegaly following treatment with gefitinib (ZD1839).
    Pascual JC; Bañuls J; Belinchon I; Blanes M; Massuti B
    Br J Dermatol; 2004 Nov; 151(5):1111-2. PubMed ID: 15541102
    [No Abstract]   [Full Text] [Related]  

  • 16. Recovery after transverse rectus abdominis myocutaneous flap breast reconstruction surgery.
    Dell DD; Weaver C; Kozempel J; Barsevick A
    Oncol Nurs Forum; 2008 Mar; 35(2):189-96. PubMed ID: 18321830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe cutaneous toxicity following treatment with gefitinib (ZD1839).
    Pascual JC; Belinchón I; Sivera F; Yuste A
    Br J Dermatol; 2005 Dec; 153(6):1222-3. PubMed ID: 16307664
    [No Abstract]   [Full Text] [Related]  

  • 18. A giant papillary carcinoma of the breast treated with mastectomy and bipedicled TRAM flap.
    Franceschini G; Salgarello M; Masetti R; Terribile D; Belli P; Costantini M; Adesi LB; Picciocchi A
    Ann Ital Chir; 2006; 77(4):341-4. PubMed ID: 17139965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer metastatic to the vulva after local recurrence occurring on a rectus abdominis myocutaneous flap: a case report and review of the literature.
    Valenzano Menada M; Papadia A; Lorenzi P; Fulcheri E; Ragni N
    Eur J Gynaecol Oncol; 2003; 24(6):577-9. PubMed ID: 14658609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
    Reimer G; Brudler O; Heinrich B; Bangerter M
    MMW Fortschr Med; 2008 Dec; 150(49-50):37-8, 40. PubMed ID: 19133368
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.